Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine

Veterinary Immunology and Immunopathology

Volumn 143, Issue 3-4, 2011, Pages 246-254

  Abbott, J R ^a   Sanou, M P ^a   Coleman, J K ^a   Yamamoto, J K ^a  

^a University of Florida   (United States)

Author keywords

Feline immunodeficiency virus; HIV vaccine; T cell epitopes

Indexed keywords

ANTIGEN; EPITOPE; FELINE LEUKEMIA VIRUS VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; GRANZYME; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VIRUS VACCINE; INTERLEUKIN 2; LIVE VACCINE; NEUTRALIZING ANTIBODY; PERFORIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOVIRUS 5; CANARYPOX VIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL PROLIFERATION; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG SAFETY; EQUINE INFECTIOUS ANEMIA VIRUS; EXPERIMENTAL CAT; EXPERIMENTAL MODEL; FELINE IMMUNODEFICIENCY VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; LENTIVIRUS INFECTION; LOW DRUG DOSE; MIXED INFECTION; NONHUMAN; NORTH AMERICA; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RISK FACTOR; SHORT SURVEY; SIMIAN IMMUNODEFICIENCY VIRUS; SURVIVAL TIME; THAILAND; VACCINATION; VIRUS LOAD; VIRUS STRAIN; WESTERN HEMISPHERE;

AIDS VACCINES; ANIMALS; CATS; CLINICAL TRIALS AS TOPIC; CONSERVED SEQUENCE; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; VACCINES, SYNTHETIC;

ANIMALIA; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

EID: 80052352105     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2011.06.019     Document Type: Short Survey

References (43)

1. Barouch D.H., Korber B. HIV-1 vaccine development after STEP. Annu. Rev. Med. 2010, 61:153-167.
2. Bello G., Velasco-de-Castro C.A., Bongertz V., Rodrigues C.A., Giacoia-Gripp C.B., Pilotto J.H., Grinsztejn B., Veloso V.G., Morgado M.G. Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1. J. Med. Virol. 2009, 81:1681-1690.
3. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., Gilbert P.B., Lama J.R., Marmor M., del Rio C., McElrath M.J., Casimiro D.R., Gottesdiener K.M., Chodakewitz J.A., Corey L., Robertson M.N. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
4. Blankson J.N. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses?. Antivir. Res. 2010, 85:295-302.
5. Boaz M.J., Waters A., Murad S., Easterbrook P.J., Vyakarnam A. Presence of HIV-1 gag-specific IFN-γ+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J. Immunol. 2002, 169:6376-6385.
6. Coleman J.K., Pu R., Martin M., Sato E., Yamamoto J.K. HIV-1 p24 vaccine protects cats against FIV. AIDS 2005, 19:1457-1466.
7. Coleman J.K., Pu R., Yamamoto J.K. Efficacy of HIV-1 and FIV subunit vaccines against FIV. J. Immunol. 2009, 182:132-133. (Immunology 2009 Meeting Abstract).
8. Chong S.Y., Egan M.A., Kutzler M.A., Megati S., Masood A., Roopchard V., Garcia-Hand D., Montefiori D.C., Quiroz J., Rosati M., Schadeck E.B., Boyer J.D., Pavlakis G.N., Weiner D.B., Sidhu M., Eldridge J.H., Israel Z.R. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine 2007, 25:4967-4982.
9. Dean G.A., LaVoy A., Burkhard M.J. Peptide mapping of feline immunodeficiency virus by IFN-γ ELISPOT. Vet. Immunol. Immunopath. 2004, 100:49-59.
10. Elyar J.S., Tellier M.C., Soos J.M., Yamamoto J.K. Perspectives on FIV vaccine development. Vaccine 1997, 15:1437-1444.
11. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F., Rgp120 HIV Vaccine Study Group Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 2005, 191:654-665.
12. Gardner M.B. HIV vaccine development. The AIDS Knowledge Base 1994, Little Brown, Co., Boston, pp. 3.6-1-3.6-5. 2nd ed. P.T. Kohen, M.A. Sande, P. Volberdine (Eds.).
13. Gilbert P.B., Peterson M.L., Follmann D., Hudgens M.G., Francis D.P., Gurwith M., Heyward W.L., Jobes D.V., Popovic V., Self S.G., Sinangil F., Burke D., Berman P.W. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 2005, 191:666-677.
14. Gilbert P., Wang M., Wrin T., Petropoulos C., Gurwith M., Sinangil F., D'Souza P., Rodriguez-Chavez I.R., DeCamp A., Giganti M., Berman P.W., Self S.G., Montefiori D.C. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis. 2010, 202:595-605.
15. Hutnick N.A., Carnathan D.G., Dubey S.A., Makedonas G., Cox K.S., Kierstead L., Ratcliffe S.J., Robertson M.N., Casimiro D.R., Ertl H.C., Betts M.R. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat. Med. 2009, 15:876-878.
16. Jones N.G., DeCamp A., Gilbert P., Peterson M.L., Gurwith M., Cao H. AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection. Vaccine 2009, 27:1136-1140.
17. Karnasuta C., Paris R.M., Cox J.H., Nitayaphan S., Pitisuttithum P., Thongcharoen P., Brown A.E., Gurunathan S., Tartaglia J., Heyward W.L., McNeil J.G., Birx D.L., de Souza M.S., Thai AIDS Vaccine Evaluation Group, Thailand Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005, 23:2522-2529.
18. Kim J.J., Simbiri K.A., Sin J.I., Dang K., Oh J., Dentchev T., Lee D., Nottingham L.K., Chalian A.A., McCallus D., Ciccarelli R., Agadjanyan M.G., Weiner D.B. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J. Interferon Cytokine Res. 1999, 19:77-84.
19. Koff W.C., Johnson P.R., Watkins D.I., Burton D.R., Lifson J.D., Hasenkrug K.J., McDermott A.B., Schultz A., Zamb T.J., Boyle R., Desrosiers R.C. HIV vaccine design: insights from live attenuated SIV vaccines. Nat. Immunol. 2006, 7:19-23.
20. Leitner, T., Korber, B., Daniels, M., Calef, C., Foley, B., 2005. HIV-1 Subtype and Circulating Recombinant Form (CRF) Reference Sequences. http://www.hiv.lanl.gov/content/sequence/HIV/REVIEWS/reviews.
21. Lichterfeld M., Kaufmann D.E., Yu X.G., Mui S.K., Addo M.M., Johnston M.N., Cohen D., Robbins G.K., Pae E., Alter G., Wurcel A., Stone D., Rosenberg E.S., Walker B.D., Altfeld M. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J. Exp. Med. 2004, 200:701-712.
22. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., Defawe O.D., Carter D.K., Hural J., Akondy R., Buchbinder S.P., Robertson M.N., Mehrotra D.V., Self S.G., Corey L., Shiver J.W., Casimiro D.R., Step Study Protocol Team HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 2008, 372:1894-1905.
23. Nitayaphan S., Pitisuttithum P., Karnasuta C., Eamsila C., de Souza M., Morgan P., Polonis V., Benenson M., VanCott T., Ratto-Kim S., Kim J., Thapinta D., Garner R., Bussaratid V., Singharaj P., el-Habib R., Gurunathan S., Heyward W., Birx D., McNeil J., Brown A.E., Thai AIDS Vaccine Evaluation Group Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J. Infect. Dis. 2004, 90:702-706.
24. O'Brien K.L., Liu J., King S.L., Sun Y.H., Schmitz J.E., Lifton M.A., Hutnick N.A., Betts M.R., Dubey S.A., Goudsmit J., Shiver J.W., Robertson M.N., Casimiro D.R., Barouch D.H. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat. Med. 2009, 15:873-8735.
25. Pistello M., Bonci F., Zabogli E., Conti F., Freer G., Maggi F., Stevenson M., Bendinelli M. Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus. J. Virol. 2010, 84:3845-3856.
26. Pitisuttithum P., Nitayaphan S., Thongcharoen P., Khamboonruang C., Kim J., de Souza M., Chuenchitra T., Garner R.P., Thapinta D., Polonis V., Ratto-Kim S., Chanbancherd P., Chiu J., Birx D.L., Duliege A.M., McNeil J.G., Brown A.E., Thai AIDS Vaccine Evaluation Group Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J. Infect. Dis. 2003, 188:219-227.
27. Pitisuttithum P., Berman P.W., Phonrat B., Suntharasamai P., Raktham S., Srisuwanvilai L.O., Hirunras K., Kitayaporn D., Kaewkangwal J., Migasena S., Sheppard H.W., Li E., Chernow M., Peterson M.L., Shibata R., Heyward W.L., Francis D.P. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J. Acquir. Immune Defic. Syndr. 2004, 37:1160-1165.
28. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., Hu D., Tappero J.W., Choopanya K., Bangkok Vaccine Evaluation Group Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 2006, 194:1661-1671.
29. Pu R., Paredes G., Yamamoto J.K. FIV vaccine update. Am. Assoc. Feline Practitioners 2004, 103-107.
30. Pu R., Sato E., Yamamoto J.K. Feline immunodeficiency virus (FIV)-cat model for AIDS: T-cell immunity important for prophylactic vaccine protection. XVI Intl. Confer. AIDS 2006, 2006:290. [Abstract THP0016].
31. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H., MOPH-TAVEG Investigators Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220.
32. Ruprecht R.M. Live attenuated AIDS viruses as vaccines: promise or peril?. Immunol. Rev. 1999, 170:135-149.
33. Shen T., Liang H., Tong X., Fan X., He X., Ma Y., Xiang W., Shen R., Zhang X., Shao Y. Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence. Vaccine 2006, 24:738-749.
34. Siegel F., Kurth R., Norley S. Neither whole inactivated virus immunogen nor passive immunoglobulin transfer protects against SIVagm infection in the African green monkey natural host. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995, 8:217-226.
35. Tatsis N., Lasaro M.O., Lin S.W., Haut L.H., Xiang Z.Q., Zhou D., Dimenna L., Li H., Bian A., Abdulla S., Li Y., Giles-Davis W., Engram J., Ratcliffe S.J., Silvestri G., Ertl H.C., Betts M.R. Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens. J. Immunol. 2009, 182:6587-6599.
36. Uhl E.W., Heaton-Jones T., Pu R., Yamamoto J.K. FIV vaccine development and its importance to veterinary and human medicine: a review. Vet. Immunol. Immunopath. 2002, 90:113-132.
37. Uhl E.W., Martin M., Coleman J., Yamamoto J.K. Advances in FIV vaccine technology. Vet. Immunol. Immunopath. 2008, 123:65-80.
38. United States Department of Agriculture, 2010. USDA Veterinary Biological Products Licensees and Permittees, June. http://www.aphis.usda.gov/animal_health/vet_biologics/publications/CurrentProdCodeBook.pdf.
39. Watkins D.I., Burton D.R., Kallas E.G., Moore J.P., Koff W.C. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med. 2008, 14:617-621.
40. Weiner D.B. RV144: old vs. new. Hum. Vaccine 2010, 6:159-161.
41. Yamamoto J.K., Pu R., Sato E., Hohdatsu T. FIV pathogenesis and development of a dual-subtype FIV vaccine. AIDS 2007, 21:547-563.
42. Yamamoto J., Coleman J., Pu R., Levy J. FIV-cat model for selecting viral proteins for HIV-1 and FIV vaccines 2009, 245 [Abstract 521].
43. Yamamoto J.K., Sanou M.P., Abbott J.R., Coleman J.K. Feline immunodeficiency virus model for designing HIV/AIDS vaccines. Curr. HIV Res. 2010, 8:14-25.